StreetInsider.com News Articles

Decision by Euronext to Classify the Asset Contribution of the H4 Orphan Pharma License to TheraVet as a Reverse Takeover

Tue, 28 Jan 2025 10:00:00 -0500

GOSSELIES, Belgium--(BUSINESS WIRE)-- Regulatory News:

EGEIRO Pharma (ISIN Code: BE0974387194 - Mnemonic: ALVET), a biopharmaceutical company specializing in the repositioning and reformulation of existing drugs, in particular for Idiopathic Pulmonary Fibrosis, announces that it has been informed of Euronext’s decision to classify the asset contribution of a license from H4 Orphan Pharma to TheraVet S.A. as a reverse takeover (RTO). This decision is based on two major factors: the contribution of a license valued at 14 million euros, significantly modifying TheraVet S.A.’s asset structure, and the company’s strategic repositioning towards human health.

In accordance with the Euronext instruction on

Decision by Euronext to Classify the Asset Contribution of the H4 Orphan Pharma License to TheraVet as a Reverse Takeover

Tue, 28 Jan 2025 10:00:00 -0500

GOSSELIES, Belgium--(BUSINESS WIRE)-- Regulatory News:

In accordance with the Euronext instruction on

Decision by Euronext to Classify the Asset Contribution of the H4 Orphan Pharma License to TheraVet as a Reverse Takeover

Tue, 28 Jan 2025 10:00:00 -0500

GOSSELIES, Belgium--(BUSINESS WIRE)-- Regulatory News:

In accordance with the Euronext instruction on

Decision by Euronext to Classify the Asset Contribution of the H4 Orphan Pharma License to TheraVet as a Reverse Takeover

Tue, 28 Jan 2025 10:00:00 -0500

GOSSELIES, Belgium--(BUSINESS WIRE)-- Regulatory News:

In accordance with the Euronext instruction on

Decision by Euronext to Classify the Asset Contribution of the H4 Orphan Pharma License to TheraVet as a Reverse Takeover

Tue, 28 Jan 2025 10:00:00 -0500

GOSSELIES, Belgium--(BUSINESS WIRE)-- Regulatory News:

In accordance with the Euronext instruction on

Decision by Euronext to Classify the Asset Contribution of the H4 Orphan Pharma License to TheraVet as a Reverse Takeover

Tue, 28 Jan 2025 10:00:00 -0500

GOSSELIES, Belgium--(BUSINESS WIRE)-- Regulatory News:

In accordance with the Euronext instruction on

EGEIRO's Board of Directors Acknowledges the Resignation of Enrico Bastianelli and Modifies Its Governance

Mon, 18 Nov 2024 12:00:00 -0500

GOSSELIES, Belgium--(BUSINESS WIRE)-- Regulatory News:

EGEIRO Pharma (ISIN : BE0974387194 - mnemo : ALVET), a biopharmaceutical company specializing in the repositioning and reformulation of existing drugs, notably in Idiopathic Pulmonary Fibrosis, announces that its Board of Directors meeting on November 15, 2024 has acknowledged the resignation of Enrico Bastianelli as a Director and has decided to modify its governance. Gaëtan Terrasse has been appointed Managing Director and Emmanuel Huynh Chairman. Catherine Bur remains a director.

About EGEIRO Pharma

EGEIRO Pharma is a biopharmaceutical company specializing in the repositioning and reformulation of existing drugs to deliver impactful improvements for patients and

EGEIRO's Board of Directors Acknowledges the Resignation of Enrico Bastianelli and Modifies Its Governance

Mon, 18 Nov 2024 12:00:00 -0500

GOSSELIES, Belgium--(BUSINESS WIRE)-- Regulatory News:

About EGEIRO Pharma

EGEIRO Pharma is a biopharmaceutical company specializing in the repositioning and reformulation of existing drugs to deliver impactful improvements for patients and

EGEIRO's Board of Directors Acknowledges the Resignation of Enrico Bastianelli and Modifies Its Governance

Mon, 18 Nov 2024 12:00:00 -0500

GOSSELIES, Belgium--(BUSINESS WIRE)-- Regulatory News:

About EGEIRO Pharma

EGEIRO Pharma is a biopharmaceutical company specializing in the repositioning and reformulation of existing drugs to deliver impactful improvements for patients and

EGEIRO's Board of Directors Acknowledges the Resignation of Enrico Bastianelli and Modifies Its Governance

Mon, 18 Nov 2024 12:00:00 -0500

GOSSELIES, Belgium--(BUSINESS WIRE)-- Regulatory News:

About EGEIRO Pharma

EGEIRO Pharma is a biopharmaceutical company specializing in the repositioning and reformulation of existing drugs to deliver impactful improvements for patients and

EGEIRO's Board of Directors Acknowledges the Resignation of Enrico Bastianelli and Modifies Its Governance

Mon, 18 Nov 2024 12:00:00 -0500

GOSSELIES, Belgium--(BUSINESS WIRE)-- Regulatory News:

About EGEIRO Pharma

EGEIRO Pharma is a biopharmaceutical company specializing in the repositioning and reformulation of existing drugs to deliver impactful improvements for patients and

EGEIRO's Board of Directors Acknowledges the Resignation of Enrico Bastianelli and Modifies Its Governance

Mon, 18 Nov 2024 12:00:00 -0500

GOSSELIES, Belgium--(BUSINESS WIRE)-- Regulatory News:

About EGEIRO Pharma

EGEIRO Pharma is a biopharmaceutical company specializing in the repositioning and reformulation of existing drugs to deliver impactful improvements for patients and

TheraVet Becomes EGEIRO Pharma

Tue, 29 Oct 2024 02:30:00 -0500

Minutes of the TheraVet Extraordinary General Meeting of October 28, 2024

GOSSELIES, Belgium--(BUSINESS WIRE)-- Regulatory News:

TheraVet (ISIN: BE0974387194 - ticker: ALVET), a pioneering company in the management of osteoarticular diseases in pets, informs its shareholders that its Extraordinary General Meeting (“EGM”) was held on Monday October 28, 2024 at 10:00 am in the offices of the Berquin law firm, 11 avenue Lloyd George, 1000 Brussels, in the presence of Simon Wheeler, Chairman of the Board of Directors.

The number of shares held by shareholders present, represented or voting by mail was 504,063, giving a quorum of 14.12%.

All resolutions

TheraVet Becomes EGEIRO Pharma

Tue, 29 Oct 2024 02:30:00 -0500

Minutes of the TheraVet Extraordinary General Meeting of October 28, 2024

GOSSELIES, Belgium--(BUSINESS WIRE)-- Regulatory News:

The number of shares held by shareholders present, represented or voting by mail was 504,063, giving a quorum of 14.12%.

All resolutions

TheraVet Becomes EGEIRO Pharma

Tue, 29 Oct 2024 02:30:00 -0500

Minutes of the TheraVet Extraordinary General Meeting of October 28, 2024

GOSSELIES, Belgium--(BUSINESS WIRE)-- Regulatory News:

The number of shares held by shareholders present, represented or voting by mail was 504,063, giving a quorum of 14.12%.

All resolutions

TheraVet Becomes EGEIRO Pharma

Tue, 29 Oct 2024 02:30:00 -0500

Minutes of the TheraVet Extraordinary General Meeting of October 28, 2024

GOSSELIES, Belgium--(BUSINESS WIRE)-- Regulatory News:

The number of shares held by shareholders present, represented or voting by mail was 504,063, giving a quorum of 14.12%.

All resolutions

TheraVet Becomes EGEIRO Pharma

Tue, 29 Oct 2024 02:30:00 -0500

Minutes of the TheraVet Extraordinary General Meeting of October 28, 2024

GOSSELIES, Belgium--(BUSINESS WIRE)-- Regulatory News:

The number of shares held by shareholders present, represented or voting by mail was 504,063, giving a quorum of 14.12%.

All resolutions

TheraVet Becomes EGEIRO Pharma

Tue, 29 Oct 2024 02:30:00 -0500

Minutes of the TheraVet Extraordinary General Meeting of October 28, 2024

GOSSELIES, Belgium--(BUSINESS WIRE)-- Regulatory News:

The number of shares held by shareholders present, represented or voting by mail was 504,063, giving a quorum of 14.12%.

All resolutions

TheraVet Announces a Strategic Transformation Project Aimed at Creating a Leader in Human Idiopathic Pulmonary Fibrosis

Mon, 30 Sep 2024 01:30:00 -0500

Operation aimed at replacing TheraVet's veterinary activities with a high potential biotech program linked to the repositioning of an innovative molecule in idiopathic pulmonary fibrosis;
Operation based on a strategic agreement between TheraVet and H4Orphan, under which H4Orphan's flagship clinical program in idiopathic pulmonary fibrosis is contributed to TheraVet in exchange for the issue of new shares;
Operation aimed at accelerating the development of an innovative treatment for pulmonary fibrosis, in particular through the launch of a Phase II study, and leveraging on the complementary expertise and resources of the two companies;
Operation associated with an initial refinancing of EUR 300,0001, offering

TheraVet Announces a Strategic Transformation Project Aimed at Creating a Leader in Human Idiopathic Pulmonary Fibrosis

Mon, 30 Sep 2024 01:30:00 -0500

Operation aimed at replacing TheraVet's veterinary activities with a high potential biotech program linked to the repositioning of an innovative molecule in idiopathic pulmonary fibrosis;

Operation based on a strategic agreement between TheraVet and H4Orphan, under which H4Orphan's flagship clinical program in idiopathic pulmonary fibrosis is contributed to TheraVet in exchange for the issue of new shares;

Operation aimed at accelerating the development of an innovative treatment for pulmonary fibrosis, in particular through the launch of a Phase II study, and leveraging on the complementary expertise and resources of the two companies;

Operation associated with an initial refinancing of EUR 300,0001, offering

TheraVet Announces a Strategic Transformation Project Aimed at Creating a Leader in Human Idiopathic Pulmonary Fibrosis

Mon, 30 Sep 2024 01:30:00 -0500

Operation aimed at replacing TheraVet's veterinary activities with a high potential biotech program linked to the repositioning of an innovative molecule in idiopathic pulmonary fibrosis;

Operation based on a strategic agreement between TheraVet and H4Orphan, under which H4Orphan's flagship clinical program in idiopathic pulmonary fibrosis is contributed to TheraVet in exchange for the issue of new shares;

Operation aimed at accelerating the development of an innovative treatment for pulmonary fibrosis, in particular through the launch of a Phase II study, and leveraging on the complementary expertise and resources of the two companies;

Operation associated with an initial refinancing of EUR 300,0001, offering

TheraVet Announces a Strategic Transformation Project Aimed at Creating a Leader in Human Idiopathic Pulmonary Fibrosis

Mon, 30 Sep 2024 01:30:00 -0500

Operation aimed at replacing TheraVet's veterinary activities with a high potential biotech program linked to the repositioning of an innovative molecule in idiopathic pulmonary fibrosis;

Operation based on a strategic agreement between TheraVet and H4Orphan, under which H4Orphan's flagship clinical program in idiopathic pulmonary fibrosis is contributed to TheraVet in exchange for the issue of new shares;

Operation aimed at accelerating the development of an innovative treatment for pulmonary fibrosis, in particular through the launch of a Phase II study, and leveraging on the complementary expertise and resources of the two companies;

Operation associated with an initial refinancing of EUR 300,0001, offering

TheraVet Announces a Strategic Transformation Project Aimed at Creating a Leader in Human Idiopathic Pulmonary Fibrosis

Mon, 30 Sep 2024 01:30:00 -0500

Operation aimed at replacing TheraVet's veterinary activities with a high potential biotech program linked to the repositioning of an innovative molecule in idiopathic pulmonary fibrosis;

Operation based on a strategic agreement between TheraVet and H4Orphan, under which H4Orphan's flagship clinical program in idiopathic pulmonary fibrosis is contributed to TheraVet in exchange for the issue of new shares;

Operation aimed at accelerating the development of an innovative treatment for pulmonary fibrosis, in particular through the launch of a Phase II study, and leveraging on the complementary expertise and resources of the two companies;

Operation associated with an initial refinancing of EUR 300,0001, offering

TheraVet Announces a Strategic Transformation Project Aimed at Creating a Leader in Human Idiopathic Pulmonary Fibrosis

Mon, 30 Sep 2024 01:30:00 -0500

Operation aimed at replacing TheraVet's veterinary activities with a high potential biotech program linked to the repositioning of an innovative molecule in idiopathic pulmonary fibrosis;

Operation based on a strategic agreement between TheraVet and H4Orphan, under which H4Orphan's flagship clinical program in idiopathic pulmonary fibrosis is contributed to TheraVet in exchange for the issue of new shares;

Operation aimed at accelerating the development of an innovative treatment for pulmonary fibrosis, in particular through the launch of a Phase II study, and leveraging on the complementary expertise and resources of the two companies;

Operation associated with an initial refinancing of EUR 300,0001, offering

TheraVet Reports Its 2024 Half-year Results and Provides an Update on the Development of Its Activities

Thu, 12 Sep 2024 01:30:00 -0500

Number of BIOCERA-VET kits sold increased by 19% compared to the 1st half of 2023, and by 72% in the 2nd quarter of 2024 compared to 2nd quarter 2023

Net sales increase by 12.1%1 compared to the 1st half of 2023

Net operating loss reduced by 23% compared to the 1st half of 2023 with operating charges reduced by 13%

Cash position of €0.7 million on June 30, 2024, giving financial visibility up to November 2024

Suspension of the ViscoVet clinical trial and associated expenses pending its anticipated results

The Company continues assessing several refinancing options

The Board of